Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences, Inc. reports clinical and corporate updates as a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders. Company news centers on roluperidone, its product candidate for negative symptoms of schizophrenia, including confirmatory Phase 3 activity, clinical safety data, pharmacokinetic and pharmacodynamic findings, and discussions related to trial design.
Recurring updates also cover financial results, research and development spending, private financing tied to the roluperidone program, investor and scientific conference participation, and governance changes. Minerva’s disclosures are focused on the development path for CNS product candidates rather than commercial product sales.
Minerva Neurosciences, Inc. reported its first-quarter 2024 financial results, including an update on the roluperidone NDA and completion of a Phase 1b clinical trial for patients with schizophrenia. The company's R&D expenses increased due to FDA review costs, while G&A expenses decreased. The net loss for the quarter was $8.6 million. Cash position decreased to $34.9 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.